The FreeStyle Libre 2 & 3 CGM System Through Medicare & Private Insurance+
- Easy to use. Easy to apply. Easy to monitor.
- Real-time glucose alarms with alerts when out of range.
- Discreet sensor.
+ Smart device sold separately. FreeStyle Libre 3 now available to commercial insurance plans. To confirm your coverage and costs, speak with Byram Healthcare and your insurance provider. Deductibles, co-pays, and other conditions apply. Performance You Can Count On2
Real-time glucose readings are sent every minute to your smartphone‡ and can be viewed with a quick glance§.
Reduce A1C
Significantly reduce your A1C 6,7
DISCREET
The world’s smallest5, thinnestII, and most discreet5 sensor—smaller than two stacked pennies5
EASY
Painless to apply5 and wear5 with a simple 1-piece applicator
RELIABLE
Optional, real-time glucose alarms¶ let you know the minute your glucose is too high or too low
FDA CLEARED
Our CGM systems are FDA-cleared for adults and children with diabetes, ages 4 years and above2. Swap sensors at your convenience.
NO FINGERSTICKS*†
CGM uses a small sensor paired with your smartphone‡ or a reader, instead of fingersticks.*†
The FreeStyle Libre App: Know it all from your phone
The FreeStyle Libre app gives you the freedom to view your glucose readings on a compatible smartphone instead of a reader.
You can download the FreeStyle Libre app from the App Store or Google Play for free.
Watch Video on the New FreeStyle Libre 3
At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.
‡ The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check their compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.
¶ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.
§ 60-minute warm-up required when starting the sensor.
* Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
† Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
References: 1. Fokkert, Marion, et al. "Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 2. FreeStyle Libre 3 User’s Manual. 3. Bolinder, Jan, et al. "Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial." The Lancet 10057, no. 388 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 4. Yaron, Marianna, et al. "Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes." Diabetes Care 42, no. 7 (2019); 1178-1184. https://doi.org/10.2337/dc18-0166. 5. Data on File. Abbott Diabetes Care.
FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
Freestyle Libre is a registered trademark of Abbott.6. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 7. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9.
